In January, 2022, due to Covid cases has been severely raised, UEL, contacted Pfizer-cne of the world's premier biopharmaceutical companies to buy the patent rights for Pfizer-BioTech COVID-19 Vaccine production. Pfizer agreed to transfer with total costs of USD1,000,000 on credit, payment would be settled in February 2023. The patent rights expires after 10 years according to legal clause, however, based on optimistic anticipation on herd immunity, UEL oy expects to make use of this Vaccine patent for 5 years from now and then dispose of this patens rights. Exchange rate at the date of transactions was USD 1 -CHF 0.89, at year end was USD 1-CHF 0,99. Amortisation expenses would move to Admin expenses

Require: book entry